Chances are when you think of Detroit, the last thing you think of is biomedical research. You probably have visions in your head of broken down factories, poverty, crime, and general … Continue Reading Detroit: America’s Hottest Biomedical City?
Beauty is in the eye of the beholder and for some beauty comes by how they look. As we get older, slowly begin to resemble a raisin (I’m kidding), some … Continue Reading EVOLUS RALLIES, Up more than 46%! Botox has a new rival… Hello Jeuveau!
If you are scrolling on social media or turn on the TV recently, you may see a familiar name on your feed. Who am I talking about? Well if you … Continue Reading The Once Praised FRAUD of Theranos: Elizabeth Holmes
What a week! From the approval of Evolus to MacroGenics announcing that they have positive results from their late stage clinical trial. Pharma and Biotechnology is bringing out the big … Continue Reading MacroGenics stock SOARS after beating Herceptin
With the development and launch of the Bitcoin cryptocurrency back in 2009, thousands of other crypto platforms have been developed. Each of these platforms seeking to change how things are … Continue Reading New kids on the block, Crypto Healthcare start ups of 2019
Today, China is leading the world in this field of research and applications. More than a billion dollars poured into the country to fund the research of several drug developers. … Continue Reading Biotechnology Advancements in China
Kenneth C. Frazier is one of the most recognized African American CEOs in America today. Frazier has been a lawyer, corporate general counsel, pharmaceutical executive, and also served on the … Continue Reading CEO SPOTLIGHT: Kenneth Frazier of Merck
Sun Pharma (NSE: SUNPHARMA) received FDA approval for a re-formulation that yielded a stronger strength of Docefrez. . An anti-neoplastic agent that carries anti-tumor activity against tumors. Docefrez receives an … Continue Reading FDA gives the greenlight to Sunpharma for an Upgraded Docetaxel (DoceFrez)
United Health Group is suing its former executive, David Smith, the former VP of Product/Corporate Strategy for Optum Services, for a breach of contract over intellectual property. As the executive … Continue Reading Corporate Trade Secrets? Amazon’s new executive…
Drug pricing was a hot topic for Americans in 2016, from Hillary Clinton to President Trump, an immense pressure has been put on pharma to lower their drug prices. If … Continue Reading Can you lower the price Pharma?
Bristol Myers Squibb (BMS) has agreed to acquire Celgene for $102.43 dollars per share, valuing Celgene at 74 Billion dollars. In exchange Celgene stock holders will get $50 dollars in … Continue Reading Buyout of the Century, with 74 Billion in hand Bristol-Myers Squibbs Acquires Celgene
Biotechnology and pharmaceuticals is an interesting industry, if you are a professional in Pharma, you understand that tremendous wealth has been made. Creating new billionaires by treating diseases but it … Continue Reading The Fear of Penny Stocks